The coronavirus disease 2019 (COVID-19) pandemic is caused by the severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, which is defined by its positive …

Background Limited information is available on the effectiveness of the BBIBP-CorV
(Sinopharm, Beijing CNBG) vaccine, especially in the elderly, despite the fact that it is …

Vaccination against coronavirus disease 2019 (COVID-19) has become an important public
health solution. Developing a safe and effective vaccine against COVID-19 is a viable long …

To determine the antibody responses elicited by different vaccines against SARS‐CoV‐2,
we compared antibody responses in individuals 3 months post‐vaccination in those who …

Many available SARS-CoV-2 vaccines demonstrated good humoral response, but studies
directly comparing their immunogenicity in the general population are lacking. We evaluated …

The Republic of Serbia applied the booster dose of the following COVID-19 vaccines:
BNT162b2 mRNA (Pfizer-BioNTech), Sinopharm BBIBP-CorV (Vero Cell®), Gam-COVID …

Numerous vaccines have been generated to decrease the morbidity and mortality of COVID-
19. This study aims to evaluate the immunogenicity of the heterologous boosts by BioNTech …

Insufficient data have been reported about the effect of the inactivated SARS-CoV-2 vaccine
(BBIBP-CorV) on the humoral response through time in healthcare workers (HCW). This …

Fifty five percent of the Pakistani population is still unvaccinated with the two-dose protocol
of COVID-19 vaccines. This study was undertaken to determine the seroconversion rate and …

Older people in nursing homes (NH) have been hit particularly hard by the COVID-19
pandemic. We conducted a retrospective study of three outbreaks of COVID-19, occurring …